Abstract
A plethora of drugs is available for the treatment of ocular allergy. Traditional treatment includes antihistamine and antihistamine/vasoconstrictor combination eyedrops. These drugs are useful, safe, and readily available. Mast cell stabilizers are safe, effective, and an important component of antiallergic therapy. Nonsteroidal anti-inflammatory drugs also have antiallergic effects. In recent years, drugs with multiple mechanisms of action have proven to be effective antiallergics. These drugs often have mast cell stabilizing, antihistaminic, and anti-inflammatory properties. Corticosteroids are considered to be more potent than other antiallergic drugs, and modifications in their molecular structures have made certain corticosteroids suitable for the treatment of ocular allergy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Bielory L: Allergic and immunologic disorders of the eye: part I: immunology of the eye. J Allergy Clin Immunol 2000, 106:805–816.
Bielory L: Allergic and immunologic disorders of the eye: part II: ocular allergy. J Allergy Clin Immunol 2000, 106:1019–1032.
Buckley RJ: Allergic eye disease—a clinical challenge. Clin Exp Allergy 1998, 28(suppl 6):39–43. This is a comprehensive review of the challenges and solutions facing the physician treating ocular allergic disease.
Verin P: Treating severe eye allergy. Clin Exp Allergy 1998, 28(suppl_6):44–48.
Hingorani M, Moodaley L, Calder VL, et al.: A randomized, placebo-controlled trial of topical cyclosporin A in steroiddependent atopic keratoconjunctivitis. Ophthalmology 1998, 105:1715–1720.
Casey R, Abelson MB: Atopic keratoconjunctivitis. Int Ophthalmol Clin 1997, 37:111–117.
Verin PH, Dicker ID, Mortemousque B: Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy 1999, 29:529–536.
Akpek EK, Hasiripi H, Christen WG, Kalayci D: A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology 2000, 107:263–269.
Asbell P, Howes J: A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997, 23:31–36.
Dell SJ, Lowry GM, Northcutt JA, et al.: A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998, 102:251–255.
Friedlaender MH: Conjunctival provocation tests: a model of human ocular allergy. Trans Am Ophthalmol Soc 1989, 87:577–597.
Richard C, Trinquand C, Bloch-Michel E: Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis: Study Group. Eur J Ophthalmol 1998, 8:207–216.
Bonini S, Schiavone M, Bonini S, et al.: Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997, 104:849–853.
Oguz H, Bitiren M, Aslan OS, Ozardali I: Efficacy of lodoxamide eye drops on tear fluid cytology of patients with vernal conjunctivitis. Acta Med Okayama 1999, 53:123–126.
Abelson MB: Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998, 81:211–218.
Corin RE: Nedocromil sodium: a review of the evidence for a dual mechanism of action. Clin Exp Allergy 2000, 30:461–468.
Ciprandi G, Catrullo A, Tosca M, et al.: Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis. J Investig Allergol Clin Immunol 1999, 9:35–38.
Sabbah A, Marzetto M: Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr Med Res Opin 1998, 14:161–170.
Tauber J, Raizman MB, Ostrov CS, et al.: A multicenter comparison of the ocular efficacy of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1998, 14:137–145. s is a multicenter comparison of two topical nonsteroidal anti-inflammatory agents for the treatment of allergic conjunctivitis
Sharma A, Gupta R, Ram J, Gupta A: Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997, 45:177–180.
Dell SJ, Schulman DG, Lowry GM, Howes J: A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis: Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol 1997, 123:791–797.
Friedlaender MH, Howes J: A double-masked, placebocontrolled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis: the Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol 1997, 123:455–464.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Friedlaender, M. Overview of ocular allergy treatment. Curr Allergy Asthma Rep 1, 375–379 (2001). https://doi.org/10.1007/s11882-001-0051-1
Issue Date:
DOI: https://doi.org/10.1007/s11882-001-0051-1